

in the T-state (inactive; NADH bound). Notably, in the unregulated Type I CS these same residues form a stable folded region composed of two large helices that are a key part of the binding site for acetyl-CoA. Kinetic analyses of both types of CS indicate a similar catalytic mechanism, suggesting that in the active R-state of *E. coli* Type II CS, the conformation of residues 262-298 will be similar to that seen in the unregulated Type I enzymes. This uniquely evolved functionality switch in the Type II CS provides the opportunity to study a novel aspect of the protein folding problem, namely how to engineer the property of reversible instability into a formerly stably folded region. We have specifically designed and determined the structures of variant enzymes to gain a better understanding of the mechanistic features of this allosterically controlled regulatory folding/unfolding system. This has resulted in a series of stepwise structural snapshots of the refolding process in going from the T to R-states in Type II CS. Supported by the Natural Sciences and Engineering Research Council of Canada.

Keywords: enzyme allostery, protein folding, enzyme regulation

### P04.02.89

*Acta Cryst.* (2008). A64, C258

#### Crystal structure analysis of human membrane integrated protein leukotriene C<sub>4</sub> synthase

Hideo Ago<sup>1</sup>, Yoshihide Kanaoka<sup>2</sup>, Daisuke Irikura<sup>1,2</sup>, Bing Lam<sup>2</sup>, Tatsuro Shimamura<sup>1</sup>, Frank Austen<sup>2</sup>, Masashi Miyano<sup>1</sup>

<sup>1</sup>RIKEN SPring-8 Center Harima Institute, Structural Biophysics Laboratory, 1-1-1, Kouto, Sayo, Hyogo, 679-5148, Japan, <sup>2</sup>Harvard Medical School/Brigham Women's Hospital, Boston, Massachusetts 02115, USA, E-mail: ago@spring8.or.jp

Human membrane integrated protein is one of the most exciting target for protein crystallographers, due to the difficulties in protein preparation as well as crystallographic work. In the year 2007, the structures of three human membrane proteins were determined crystallographically first. Leukotriene C<sub>4</sub> synthase (LTC<sub>4</sub>S) is one of the three human membrane integrated proteins. LTC<sub>4</sub>S, which is a membrane integrated protein existing in nuclear membrane, catalyzes the conjugation between leukotriene (LT) A<sub>4</sub> and glutathione (GSH) to form LTC<sub>4</sub>. LTC<sub>4</sub> and its metabolites LTD<sub>4</sub> and LTE<sub>4</sub> are components of slow reacting substance of anaphylaxis, and they are called cysteinyl leukotrienes (Cys-LTs) because they have a cysteine moiety commonly. Cys-LTs are lipid mediators involved in smooth muscle constriction and inflammation, particularly in asthma. LTC<sub>4</sub>S is the membrane protein responsible for the biosynthesis of Cys-LTs and a potential target for drug discovery. The crystal structure of human LTC<sub>4</sub>S was determined at 3.3Å resolution using the recombinant LTC<sub>4</sub>S. We established the over-expression system using *Schizosaccharomyces pombe*, and we also used the expression system for the preparation of the selenomethionine derivative of LTC<sub>4</sub>S with a Leu121Met mutation for the MAD phase calculation as well as the native LTC<sub>4</sub>S with a histidine tag. In the crystal structure LTC<sub>4</sub>S forms trimer structure, and there is a V-shape substrate binding cleft between two adjacent monomers. GSH, which is one of the substrates, was co-crystallized with LTC<sub>4</sub>S, bound at the upper space of the V-shape cleft. Based on the crystal structure, we proposed the acid-base catalytic mechanism, and Arg31 from a monomer and Arg104 from the other monomer exert the acid and base, respectively.

Keywords: membrane protein structures, X-ray crystallography of biological macromolecules, drug targets

### P04.02.90

*Acta Cryst.* (2008). A64, C258

#### Structural insights into substrate specificity of isomaltase from *Saccharomyces cerevisiae*

Keizo Yamamoto<sup>1</sup>, Hideo Miyake<sup>2</sup>, Masami Kusunoki<sup>3</sup>, Shigeyoshi Osaki<sup>1</sup>

<sup>1</sup>Nara Medical University, Medicine, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan, <sup>2</sup>Faculty of Bioresources, Mie University, 1577 Kurimamachiya-cho, Tsu, Mie, 514-8507, Japan, <sup>3</sup>Faculty of Engineering, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan, E-mail: kama@naramed-u.ac.jp

Oligo-1,6-glucosidase (dextrin 6- $\alpha$ -D-glucanohydrolase; EC 3.2.1.10) generally hydrolyzes nonreducing terminal  $\alpha$ -1,6-glucosidic bonds of isomaltooligosaccharides and  $\alpha$ -limit dextrin more rapidly than those of isomaltose. However, oligo-1,6-glucosidase from *Saccharomyces cerevisiae* (isomaltase) preferentially hydrolyzes isomaltose and weakly acts on isomaltooligosaccharides. To understand the difference in substrate specificity between isomaltase and other oligo-1,6-glucosidase from a structural view point, the crystal structure of isomaltase and isomaltase complexed with maltose as a competitive inhibitor were determined. Isomaltase was crystallized by the hanging drop vapor diffusion method using PEG3350 as a precipitant. An inhibitor complex was cocrystallized under the same conditions in the presence of 0.2 M maltose. Data sets for structural analysis were collected on synchrotron radiation to 1.6 Å resolution for the native and maltose complex. The crystals belong to the monoclinic space group C2 with the cell dimensions  $a=95.7$  Å,  $b=115.4$  Å,  $c=61.8$  Å,  $\beta=91.2^\circ$  and one 67 kDa molecule per asymmetric unit. The Overall structural features of isomaltase are similar to those of other GH family 13 enzymes such as  $\alpha$ -amylases and *Bacillus cereus* oligo-1,6-glucosidase. It consists of three domains containing a  $(\beta/\alpha)_8$  barrel structure. This reveals that the entrance of the active site cleft is narrowed by Tyr158, His280, and a loop between 310 to 315, thus disaccharide binds most efficiently in the active site for hydrolysis. The glucose residue of the nonreducing end is buried deeply at the bottom of the cleft, and tightly bound by nine hydrogen bonds and a stacking interaction with Tyr72. However, no structural change is observed before and after maltose binding.

Keywords: glycosyl hydrolases, isomaltase, substrate specificity

### P04.02.91

*Acta Cryst.* (2008). A64, C258-259

#### Mechanism for formation of Arg-AMP in help of tRNA on the basis of structure of ArgRS, tRNA and ATP

Michiko Konno<sup>1</sup>, Emiko Uchikawa<sup>1</sup>, Yukie Mori<sup>1</sup>, Tomomi Sumida<sup>1,2</sup>, Tatsuo Yanagisawa<sup>2</sup>, Shun-ichi Sekine<sup>2</sup>, Shigeuki Yokoyama<sup>2</sup>

<sup>1</sup>Ochanomizu University, Department of Chemistry, Faculty of Science, 2-1-1 Otsuka, Bunkyo-ku, Tokyo, 112-8610, Japan, <sup>2</sup>University of Tokyo, Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan, E-mail: konno@cc.ocha.ac.jp

In arginyl- and glutaminyl-tRNA synthetases (ArgRS, GlnRS) from investigated all species, no ATP-PPi exchange reaction is observed in the absence of cognate tRNA and in the presence of their tRNA treated with periodate. The pyrophosphorolysis reaction of synthetic Arg-AMP is also not observed in the absence of tRNA. The detailed mechanism through which 2'OH of the ribose of the 3' end Ade76 of the cognate tRNA accelerates these reactions has been remained

as problem to be solved. We determined a crystal structure of a complex of ArgRS from *Pyrococcus horikoshii*, tRNA<sup>Arg</sup><sub>CCU</sub> and ATP analog with  $R_{\text{factor}} = 0.215$  ( $R_{\text{free}} = 0.259$ ) at 2.0 Å resolution and could give one solution for this problem using newly obtained structural information about position of ATP. The experimental results show that the ArgRS protein lacking the additional N-terminal domain characteristic for ArgRS possesses sufficient catalytic activity in the aminoacylation reaction for tRNA. Modeling of relative positions of amino acid, Ade76 of tRNA and ATP on ArgRS was made to find the suitable position to tRNA-assisted formation mechanism of Arg-AMP. It was found that formation of hydrogen bond between 2'OH of Ade76 of tRNA and O2 of carboxy group -C-O2H=O1 of arginine can be achieved in one conformation by rotation around C-α-C of carboxy group. In ATP-PPi exchange reaction at low pH, reversible conversion between C=O1 and C-O1-Pα is controlled by the formation of this hydrogen bond. On the other hand, at pH8.0, experimental results in the deacylation reaction of Arg-tRNA is also understood by mechanism that NH<sup>+</sup> of guanidium group -N<sup>+</sup>H=C-(NH<sub>2</sub>)<sub>2</sub> of Arg-tRNA donates a proton to C=O2 of ester bond of Arg-tRNA, resulting in carbonium C<sup>+</sup>-O2H. We discuss in detail these mechanisms.

Keywords: aminoacyl-tRNA synthetases, tRNA, catalytic mechanisms

## P04.02.92

*Acta Cryst.* (2008). A64, C259

### Crystal structures of α-amino-ε-caprolactam racemase from *Achromobacter obae*

Seiji Okazaki<sup>1</sup>, Atsuo Suzuki<sup>2</sup>, Tsunehiro Mizushima<sup>3</sup>, Hidenobu Komeda<sup>4</sup>, Yasuhisa Asano<sup>5</sup>, Takashi Yamane<sup>6</sup>

<sup>1</sup>Nagoya University, Department of Biotechnology, School of Engineering, Fur-cho, Chikusa, Nagoya, Aichi Prefecture, 464-8603, Japan, <sup>2</sup>Nagoya University, Fur-cho, Chikusa, Nagoya, Aichi Prefecture, 464-8603, Japan, <sup>3</sup>Nagoya University, Fur-cho, Chikusa, Nagoya, Aichi Prefecture, 464-8603, Japan, <sup>4</sup>Toyama Prefectural University, Kurokawa 5180, Imizu, Toyama Prefecture, 939-0398, Japan, <sup>5</sup>Toyama Prefectural University, Kurokawa 5180, Imizu, Toyama Prefecture, 939-0398, Japan, <sup>6</sup>Nagoya University, Fur-cho, Chikusa, Nagoya, Aichi Prefecture, 464-8603, Japan, E-mail: okazaki.seiji@d.mbox.nagoya-u.ac.jp

α-Amino-ε-caprolactam (ACL) racemase (EC 5.1.1.15) is a 51 kDa enzyme that catalyzes the interconversion of L- and D-ACL. Recently, amino acid amide racemizing activity was found in ACL racemase [1], and the combined method of ACL racemase with D-stereospecific amino acid amidase has been developed for industrial D-amino acid production from D,L-amino acid amide [2]. To clarify the structure-function relationships of ACL racemase, the crystal structures of the native and ε-caprolactam complex of ACL racemase were determined at 2.3 and 2.4 Å resolutions, respectively. ACL racemase belongs to the fold-type 1 group of PLP-dependent enzyme [3]. The crystal structures of serine racemase which belongs to fold-type 2 (PDB ID 1V71) and alanine racemase which belongs to fold-type 3(1SFT) were already determined. However, the crystal structure of fold-type 1 racemase has not been determined yet. If the structure of ACL racemase can be determined, we can understand the catalytic mechanism of racemase which belongs to fold-type 1 for the first time. The structure of ACL racemase is composed of three segments; (1) an N-terminal segment, (2) a large, pyridoxal phosphate (PLP) binding domain and (3) a C-terminal domain. The C4<sup>+</sup> in PLP covalently bonded to the ε-amino group of Lys267 forming the internal aldimine. From structural comparison with racemase belongs to fold-type 2 and 3, Lys267 and Tyr137 of ACL racemase may be candidates for two bases which are essential

for proceeding racemization. The functional significance of ACL racemase will be discussed.

Reference

- [1] Asano, Y. & Yamaguchi, S., *J. Mol. Catal. B. Enzym.* **36**, 22-29.  
[2] Asano, Y. & Yamaguchi, S., *J. Am. Chem. Soc.* **127**, 7696-7697.  
[3] Grishin *et al.*, *Protein Sci.* **4**, 1291-1304.

Keywords: enzyme structure, racemases, X-ray biocrystallography

## P04.02.93

*Acta Cryst.* (2008). A64, C259

### FBPase allosteric transition: Crystal structures of liver and muscle isoforms from rodents and human

Armin Ruf, Markus Rudolph, Catherine Joseph, Jörg Benz, Brigitte Schott, Tim Tetaz, Bruno Fol

F. Hoffmann-La Roche Ltd, Pharma Discovery Research, Bldg 65 / 36, Grenzacherstrasse 124, Basel, Basel, 4070, Switzerland, E-mail: armin.ruf@roche.com

FBPase (Fructose-1,6-bis-phosphatase) is a key enzyme in gluconeogenesis. Together with its counterpart enzyme in glycolysis, Phosphofruktokinase, FBPase regulates glucose metabolism. FBPase forms a tetramer that is allosterically inhibited by AMP. The allosteric transition from the active R-state to the inactive T-state was intensely investigated over the last 20 years both biochemically and structurally and now serves as a textbook example for allosteric regulation in proteins. However, structural knowledge on FBPase stems almost exclusively from pig kidney/liver FBPase and thus may be biased toward this organism. Muscle FBPase is reported to be 100-fold more sensitive to AMP inhibition than liver FBPase while rodent liver FBPases are roughly 10-fold less sensitive to allosteric inhibition than their human or pig counterparts. Do the textbooks convey the correct picture of the allosteric transition? Or do they purport a biased and, thus, misleading view of the pig special case? To clarify this issue we determined several crystal structures of FBPase liver and muscle isoforms from rat, mouse, and human.

Organism Tissue	Human Muscle	Human Muscle	Rat Muscle	Human Liver	Rat Liver	Mouse Liver	Mouse Liver
Inhibitor	F28P (comp.)	AMP	AMP	-	-	-	ΔMP-analog
Conformation	T	T	T	R	R	R	T
Space group	C222	C222	P1	P4 <sub>1</sub> 212 or P4 <sub>3</sub> 212	I222	P21212	C2
Cell	219Å, 227Å, 79Å	219Å, 234Å, 72Å	56Å, 87Å, 145Å, 101* 92* 92*	122Å, 122Å, 312Å	75Å, 78Å, 130Å	108Å, 81Å, 73Å	165Å, 144Å, 102Å, 123*
Molecules / ASU	4	4	8	6	1	2	6
Resolution	2.3 Å	2.3 Å	2.7 Å	2.2 Å	1.9 Å	1.8 Å	3.0 Å

Keywords: allosteric regulation, enzyme, fructose-1,6-bisphosphate

## P04.02.94

*Acta Cryst.* (2008). A64, C259-260

### Catalytic promiscuity and mechanistic determinants of ODCase - A high-resolution investigation

Masahiro Fujihashi<sup>1</sup>, Shingo Kuroda<sup>1</sup>, Lakshmi P Kotra<sup>2,3,4</sup>, Emil F Pai<sup>5,6</sup>, Kunio Miki<sup>1</sup>

<sup>1</sup>Kyoto University, Department of Chemistry, Graduate School of Science, Sakyo-ku., Kyoto, Kyoto, 6068502, Japan, <sup>2</sup>Toronto General Institute, University Health Network, Toronto, Ontario M5G 1L7, Canada, <sup>3</sup>Departments of Pharmaceutical Sciences and Chemistry, University of